By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


VistaGen Therapeutics, Inc. 

384 Oyster Point Boulevard
Suite 8
South San Francisco  California  94080  U.S.A.
Phone: 650-244-9990 Fax: 650-244-9979



Start Up

Company News
VistaGen Therapeutics, Inc. Completes $10 Million Public Offering 5/16/2016 11:58:31 AM
VistaGen Therapeutics, Inc. Announces Nasdaq Listing And Pricing Of $10.0 Million Public Offering 5/11/2016 6:12:14 AM
VistaGen Therapeutics, Inc. Appoints Jerry Gin, Ph.D., MBA To Its Board Of Directors 3/30/2016 6:22:27 AM
VistaGen Therapeutics, Inc. Bolsters Clinical And Regulatory Advisory Board With Appointments Of Distinguished Key Opinion Leaders In Depression 3/22/2016 6:52:10 AM
VistaGen Therapeutics, Inc. Secures Exclusive Worldwide Commercial Rights To Three Proprietary Stem Cell Technologies From University Health Network 12/23/2015 6:44:20 AM
VistaGen Therapeutics, Inc. Announces First Patient Dosed In NIH-Sponsored Phase 2A Study Of Orally Available AV-101 In Major Depressive Disorder 11/3/2015 6:19:02 AM
Dr. Maurizio Fava, Internationally Renowned Expert In The Field Of Depression, Joins VistaGen Therapeutics, Inc.'s Clinical And Scientific Advisory Board 10/7/2015 7:00:59 AM
Favorable Data On VistaGen Therapeutics, Inc.' AV-101 For Major Depressive Disorder Published In Peer-Reviewed Journal Of Pharmacology And Experimental Therapeutics 9/16/2015 6:28:33 AM
VistaGen Therapeutics, Inc. Receives FDA And NIH Clearance To Initiate NIH-Funded Phase 2 Study Of Orally Active AV-101 In Major Depressive Disorder 7/1/2015 11:26:06 AM
VistaGen Therapeutics, Inc. And NIH Sign Agreement For NIH-Sponsored Phase 2 Study Of Orally-Active AV-101 In Major Depressive Disorder 2/17/2015 8:07:36 AM